electroCore posted record 2025 revenue of $32.0 million, up 27% year over year, and guided to approximately 30% growth in 2026. The company also announced a leadership transition, with the CEO retiring April 1, 2026, the CFO stepping in as interim president, and a new chief operating officer joining to strengthen commercial execution. Despite an 87% gross margin and expanding prescription and wellness sales, the GAAP net loss widened to $14.0 million and year-end cash and marketable securities totaled $11.6 million.
The central strategic question is whether a hybrid model that straddles prescription neuromodulation and consumer wellness can scale fast enough to convert high gross margins into operating leverage before capital tightens. electroCore’s trajectory hinges on turning demand for non-invasive vagus nerve stimulation into payer-supported, durable revenue without blurring the clinical value proposition that underpins adoption by neurologists, pain specialists, and integrated systems.
For commercial leaders, the growth mix is telling. U.S. prescription revenue rose 25% on gammaCore and Quell Fibromyalgia, indicating continued clinician pull for non-opioid pain pathways as guidelines and health systems emphasize multimodal analgesia. Meanwhile, general wellness nearly doubled, driven by handheld devices positioned outside the medical benefit, suggesting consumers are ready to experiment with bioelectronic solutions absent reimbursement. The contrast highlights both opportunity and risk: wellness can accelerate top-line growth and brand awareness, yet payers often scrutinize crossover products for medical necessity and differentiation. A sharp 65% decline in the TAC-STIM human performance line underscores channel volatility when indications sit between athletic optimization and clinical care.
Medical Affairs will be pivotal to sustain prescription momentum and defend value as utilization expands. High gross margins create room for evidence generation, but SG&A rose significantly in 2025, and a bad-debt charge tied to a single customer flags execution exposure in concentrated channels. Real-world outcomes in chronic migraine, cluster headache, and fibromyalgia—particularly reductions in acute care visits, opioid use, and total cost of care—will be essential to secure and maintain coverage, persuade P&T committees, and enable step-through designs aligned with payer budgets. The Veterans Health Administration remains a meaningful proving ground for neuromodulation; a COO with demonstrated growth across VA pathways could help convert formulary access into consistent utilization and repeat purchase.
The update lands amid a broader revival of bioelectronic medicine and a reset in digital therapeutics. With investors favoring capital-efficient, high-margin devices, neuromodulation players that can validate outcomes and integrate into care pathways are resurfacing as credible non-pharmacologic alternatives. At the same time, financing remains selective, pushing companies toward revenue-based lending and tuck-in M&A to fill portfolio gaps—electroCore’s prior NeuroMetrix deal and term debt align with this pattern. The consumerization of health tech complicates brand architecture but expands the top of the funnel; the winners will segment rigorously, maintain clinical-grade claims for Rx lines, and avoid cannibalization or regulatory ambiguity.
Near term, watch three execution levers: payer and system-level adoption for Quell Fibromyalgia and gammaCore as real-world data matures; VA procurement and utilization cadence as a template for large integrated buyers; and the launch timing and positioning of next-gen platforms like gammaCore Emerald and its mobile app to reinforce adherence and outcomes tracking. The 30% growth target sets an ambitious bar against rising operating costs and a leadership handoff. The competitive question now is whether electroCore can transform consumer interest into payer-validated, guideline-embedded use cases fast enough to demonstrate operating leverage—before larger neuromodulation incumbents or focused start-ups seize the clinical narrative and the channel.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
